T he efficacy and safety of tesaglitazar (0.5 and 1 mg) and pioglitazone (15, 30 and 45 mg) were compared in a 24-week, randomised, double-blind study in 1,707 patients with type 2 diabetes mellitus.
Introduction
Type 2 diabetes mellitus is characterised by raised glucose levels which are associated with an increase in the risk for microvascular disease, as well as dyslipidaemia, which increases the risk of macrovascular cardiovascular disease. 1, 2 Pioglitazone and rosiglitazone are thiazolidinediones (TZDs) used in the treatment of type 2 diabetes mellitus. They offer similar control of hyperglycaemia, but pioglitazone provides more favourable improvements in high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. [3] [4] [5] [6] The distinct effects of the TZDs on lipoproteins may be attributable to their affinity for peroxisome proliferatoractivated receptor (PPAR)γ and PPARα. Rosiglitazone is a PPARγ agonist with no significant PPARα activity, 7, 8 whereas pioglitazone is predominantly a PPARγ agonist but has weak PPARα-agonist properties. 9 Stimulating PPARγ increases proliferation and differentiation of adipocytes in subcutaneous tissue, promotes apoptosis in visceral adipose tissue, increases free fatty acid (FFA) uptake into subcutaneous adipose tissue, and improves insulin sensitivity in peripheral tissues such as muscle, which increases peripheral glucose utilisation. [10] [11] [12] Stimulation of PPARα increases lipoprotein lipase (LPL) activity (causing catabolism of TG in very-lowdensity lipoproteins [VLDL] and chylomicrons), reduces secretion of VLDL, inhibits apolipoprotein (apo) C-III expression and increases high-density apolipoprotein (apoA-I and apoA-II) production, resulting in reduced TG and increased HDL-C levels. 13 Additionally, fibrates may cause favourable changes in lipoprotein particle size and subclass distribution. 14 Tesaglitazar (GALIDA™; AstraZeneca, Wilmington, DE, US) is a dual PPARα/γ agonist. 8 In contrast to the weak PPARα agonism of pioglitazone, 9 tesaglitazar has a greater affinity for this receptor than fenofibric acid. 8 In a prior study, at doses > 0.5 mg, it reduced fasting plasma glucose (FPG) levels in patients with type 2 diabetes mellitus after 12 weeks of treatment. 15 Tesaglitazar also improved other markers of glycaemic control, plasma lipids (TG, HDL-C, non-HDL-C, total cholesterol and VLDL-C) and measures associated with insulin resistance (homeostasis model assessment [HOMA] index).
The efficacy of tesaglitazar as monotherapy and in combination with other antidiabetic agents was examined in phase III studies (the GALLANT programme). Following results from these studies, the development of tesaglitazar was discontinued because its benefit-risk profile was found to provide no advantage over those of currently available therapies. We report the largest study from this programme, which compared monotherapy with tesaglitazar and pioglitazone across their respective dose ranges.
Methods GALLANT 6 (D6160C00030; clinicaltrials.gov identifier: NCT00214565) was a 24-week, randomised, doubleblind, active-controlled, multicentre study in patients with type 2 diabetes mellitus. It compared the efficacy, safety and tolerability of tesaglitazar (0.5 and 1 mg) with pioglitazone (15, 30 and 45 mg) . The study was conducted at 218 centres in North and South America, Scandinavia and the UK from August 2004 to January 2006. The study protocol conformed to the guidelines of the Declaration of Helsinki (version dated October 2000) and was approved by the Institutional Review Board at each participating institution.
Patients
Study participants were men or women aged 18 years or older. Women of childbearing age were required to use adequate methods of contraception. Entry criteria included a diagnosis of type 2 diabetes mellitus, a glycosylated haemoglobin (HbA 1C ) > 7% and < 10%, and FPG < 13.3 mmol/L (240 mg/dL). Exclusion criteria included recent treatment with TZDs or fibrates, chronic treatment with insulin, and New York Heart Association (NYHA) heart failure Class III or IV, or unstable Class I or II heart failure (i.e. those patients not considered to be in a stable condition by the study investigator).
At enrolment, all oral antidiabetic medications were discontinued and study subjects were counselled on dietary and lifestyle modification. Eligible patients entered a sixweek, single-blind, placebo run-in period. Those patients whose type 2 diabetes mellitus was not adequately controlled by diet and lifestyle changes were randomised equally to tesaglitazar (0.5 or 1 mg) or to pioglitazone (15, 30 or 45 mg) for 24 weeks, using a computer-generated list. At the end of the study, a single follow-up visit took place three weeks after stopping the study drug. Study subjects who entered the open-label extension to this study were not required to attend the follow-up visit.
The primary objective was to determine whether monotherapy with tesaglitazar 1 mg was non-inferior to monotherapy with pioglitazone 45 mg in improving glycaemic control, as measured by the absolute change from baseline in HbA 1C after 24 weeks of randomised treatment. The study also compared treatment changes with tesaglitazar or pioglitazone for the following: TG, HDL-C, non-HDL-C, low-density lipoprotein cholesterol (LDL-C), apoCIII, apoA-I, apoB, FFA, FPG, fasting insulin, and lipoprotein particle size and concentration.
Triglyceride and cholesterol were measured using enzymatic methods (Roche Diagnostics, Indianapolis, IN, US); HDL-C was measured after chemical precipitation of HDL with dextran sulphate. The Friedewald formula was used to estimate LDL-C ([total cholesterol -HDL-C] -[TG x 0.2]), except where TG concentrations were above the limit for validity (> 4.5 mmol/L), in which case LDL-C was measured by ultracentrifugation. 16 ApoA-I and apoB were measured by immunonephelometry. High-sensitivity C-reactive protein (CRP) was measured using an ultrasensitive latex-enhanced immunoassay (BN II nephelometer, Dade Behring, Newark, DE, US). Tumour necrosis factor-α (TNF-α) and intercellular adhesion molecule-1 (ICAM-1) levels were measured by EIA R&D Systems, Minneapolis, MN, US. Lipoprotein particle size and concentration were assessed by nuclear magnetic resonance (LipoScience, Raleigh, NC, US). 14 All other analyses were performed by Covance Central Laboratory Services LP (Indianapolis, IN, US). Insulin resistance was estimated using the HOMA index (FPG [mmol/L] x fasting plasma insulin [µUl/mL]/22.5]). 17 Safety and tolerability were evaluated by assessment of patient-reported adverse events (AEs), laboratory values, urinalysis, pulse, blood pressure, body weight, cardiac evaluation, and physical and electrocardiographic examinations. Hypoglycaemic events were assessed according to guidance by the Committee for Proprietary Medical Products. 18 
Statistical analysis
A total of 259 evaluable study subjects per treatment arm allowed the null hypothesis of inferiority of tesaglitazar by 0.4% or more to be rejected with 90% power, using a twosided t-test at an α of 0.05. For comparisons of HbA 1C between tesaglitazar and pioglitazone 15 mg, prespecified non-inferiority (NI) limits were 0.3%. The primary variable, comparison between tesaglitazar 1 mg and pioglitazone 45 mg in absolute change in HbA 1C from baseline to the end of the randomised treatment period, was analysed with a linear model using fixed-effect analysis of covariance (ANCOVA). All main efficacy analyses were performed with the intention-to-treat (ITT) analysis set. All comparisons, with the exception of HbA 1C , were only tested for superiority. For analyses of HbA 1C , TG, HDL-C and non-HDL-C, sequential testing was applied using the Bonferroni-Holm procedure for groups of hypotheses to control the overall significance level at 0.05. 19 The non-inferiority analysis for HbA 1C between the highest doses of tesaglitazar and pioglitazone (the primary variable) was evaluated first. If this was significant, analyses for the secondary variables were performed sequentially for groups of comparisons ordered by decreasing doses of tesaglitazar and pioglitazone (viz. 1 mg vs. 45 mg; 1 mg vs. 30 mg; 0.5 mg vs. 30 mg; 0.5 mg vs. 15 mg, respectively), with superiority analyses for HbA 1C performed as the last comparison group. If the maximum p value within a group of dose comparisons was non-significant, the sequential testing of groups using the Bonferroni-Holm procedure was stopped and all comparisons within that dose comparison group and all subsequent groups were evaluated individually. For all other variables, the overall significance levels were not adjusted for multiplicity and the results of the statistical testing must be considered to be supportive.
Results
In total, 3,945 patients entered the six-week, single-blind placebo run-in period, and 1,707 patients were randomised to treatment. Of these study subjects, 738 (43.2%) attended the follow-up visit, either following discontinuation or completion of the study; 823 (48.2%) entered the openlabel extension study.
The treatment groups were well matched for baseline and disease characteristics (table 1). The mean duration of diagnosis of type 2 diabetes mellitus was 4.6 years and the majority (79.7%) of study subjects were using at least one oral antidiabetic agent. A total of 330 study subjects (19.3%) discontinued the study during the randomised treatment period (table 1) .
Efficacy
For the primary objective of the absolute change from baseline in HbA 1C at 24 weeks, tesaglitazar 1 mg demonstrated non-inferiority to pioglitazone 45 mg (difference of -0.056 [95% confidence intervals (CI) -0.161, 0.049], pNI<0.001 for NI hypothesis; table 2, figure 1). Tesaglitazar 0.5 mg also demonstrated non-inferiority to pioglitazone 15 mg and 30 mg, in absolute change from baseline in HbA 1C at 24 weeks. With regard to the remaining variables analysed by sequen-tial testing using predefined dose comparisons, tesaglitazar 1 mg significantly improved TG, HDL-C and non-HDL-C relative to the pioglitazone 30 and 45 mg doses at 24 weeks (p<0.001). The reductions in TG with tesaglitazar 0.5 mg were also greater in the predefined comparisons with the pioglitazone 15 and 30 mg doses (p<0.001).
FPG, insulin levels and HOMA were all lower with tesaglitazar 1 mg than with pioglitazone 45, 30 and 15 mg (p<0.001) (table 3). Tesaglitazar also lowered LDL-C for all comparisons (p<0.05), except for tesaglitazar 0.5 mg versus pioglitazone 15 mg. LDL particle size was increased to a similar degree with tesaglitazar 1 mg and pioglitazone 45 mg, but was increased to a lesser extent with pioglitazone 15 and 30 mg (p<0.001). Reductions in LDL particle number were greater with tesaglitazar 1 mg than with pioglitazone at all doses (p<0.01), but for tesaglitazar 0.5 mg a greater decrease was apparent only versus pioglitazone 15 mg (p<0.05) (table 3) . GALLANT ApoA-I levels were higher with tesaglitazar 1 and 0.5 mg, compared with pioglitazone 45 mg (p<0.05). ApoB and ApoCIII levels were lower with both doses of tesaglitazar in comparison with all three doses of pioglitazone (p<0.01). Significant reductions in FFA levels were observed with tesaglitazar 1 mg, compared with the three doses of pioglitazone (p<0.01), and for tesaglitazar 0.5 mg versus pioglitazone 15 mg (p<0.05) (table 3) .
Fibrinogen levels were lowered more with the tesaglitazar 1 and 0.5 mg doses than by any pioglitazone dose at 24 weeks (p<0.001). CRP levels were lowered to a greater extent only by the tesaglitazar 1 mg dose, compared with the pioglitazone 30 and 15 mg dose groups (p<0.05). Both GALLANT 6 STUDY The primary comparison is absolute change in HbA 1C , tesaglitazar 1 mg versus pioglitazone 45 mg. Relative (%) change from baseline derived from geometric means is reported for all other variables; a n refers to number of patients in analysis group at baseline. Descriptive data are reported as mean (SD). All descriptive data and all comparative analyses are based on last observation carried forward (LOCF). For HbA 1C analysis, prespecified non-inferiority limits were 0.3% for comparisons of tesaglitazar with pioglitazone 15 mg, and 0.4% for all other comparisons; b denotes superiority comparisons which were statistically significant according to the sequential multiple comparisons procedure; c denotes non-inferiority comparisons which were statistically significant according to the sequential multiple comparisons procedure. To convert TG to mg/dL multiply by 89.3; to convert HDL-C to mg/dL multiply by 38.7 tesaglitazar and pioglitazone lowered TNF-α and tended to increase ICAM-1, but there were no statistically significant differences between the treatments.
Comparative changes from baseline in primary (HbA 1C ) and selected key secondary (TG, HDL-C and non-HDL-C) efficacy variables at 24 weeks for tesaglitazar and pioglitazone: baseline-adjusted least-squares mean changes (95% confidence intervals) from baseline

Safety
Three study subjects died during the study (one patient in the tesaglitazar 1 mg group [with interstitial lung disease] and two study subjects in the pioglitazone 30 mg group [one patient with an upper gastrointestinal haemorrhage and one patient with cardiovascular disease]). None of these deaths was considered by the investigators to be treatment-related. The frequency of serious adverse events (SAEs) was low overall (3.7%) and slightly higher in the pioglitazone groups (3.0% for both tesaglitazar 1 and 0.5 mg vs. 3.9%, 5.1% and 3.9% for pioglitazone 45, 30 and 15 mg, respectively). No SAE occurred with a frequency of > 1%. Four SAEs were considered to be treatment-related (an increase in liver enzymes and a change in mental status in two patients who received tesaglitazar 0.5 mg; one patient in the pioglitazone 45 mg group developed haematuria; and one patient devel-oped a skin rash and generalised arthritis one day after receiving pioglitazone 30 mg, diagnosed as a hypersensitivity reaction). The overall frequency of AEs leading to discontinuation from the study was low (5.1%) and similar across treatment groups, with the exception of a lower frequency (3.6%) of AEs in the tesaglitazar 0.5 mg group. Peripheral oedema was the most frequent AE; it occurred with similar frequency among the tesaglitazar 1 mg and the pioglitazone 45 mg and 30 mg groups ( There were six cases of confirmed congestive heart failure (CHF). Four occurred in the tesaglitazar 1 mg group (three of them new-onset), and two occurred in the pioglitazone 45 mg group (both new-onset).
A dose-dependent increase in serum creatinine was GALLANT 6 STUDY (table 5 ). In the tesaglitazar-treated study subjects for whom follow-up data were available, serum creatinine values tended to return towards baseline ( figure 2; table 5 ). The increases were not accompanied by changes in the urinary albumin/creatinine ratio or in urinalysis for proteinuria or haematuria. Serum creatinine levels that were greater than 1.5 times the upper limit of normal (ULN) occurred in eight study subjects in the tesaglitazar 1 mg group, four study subjects in the tesaglitazar 0.5 mg group, and two study subjects in each of the pioglitazone 30 and 15 mg groups. Absolute neutrophil count (ANC) decreased with tesaglitazar in a dose-dependent manner (table 5); the decrease at week 24 with tesaglitazar 1 mg was similar to that with pioglitazone 45 mg. There were 63 study subjects who had ANC below 1.5 x 10 9 /L; 19 cases occurred in the tesaglitazar 1 mg group, seven in the tesaglitazar 0.5 mg arm and 13, 11 and 13 in the pioglitazone 45, 30 and 15 mg dose groups, respectively. A dose-dependent decrease in haemoglobin was apparent at both doses of tesaglitazar, with a greater mean decrease in the tesaglitazar 1 mg group than in the pioglitazone 45 mg group (table 5) . Fifteen subjects (six and two in the tesaglitazar 1 and 0.5 mg dose groups, respectively; one, four and two in the pioglitazone 45, 30 and 15 mg groups, respectively) had haemoglobin < 100 g/L.
There was a dose-dependent reduction in alanine aminotransferase (ALT) with tesaglitazar and pioglitazone, which was similar for the highest doses of the two drugs (table 5). Alkaline phosphatase decreased to a greater extent in the tesaglitazar groups, compared with pioglitazone. There were 27 cases in which ALT or aspartate aminotransferase (AST) was > 3 x ULN: four and six cases in the tesaglitazar 1 and 0.5 mg groups, respectively; and six, eight and three cases in the pioglitazone 45, 30 and 15 mg groups, respectively.
Discussion
The primary outcome for the study was achieved: tesaglitazar 1 mg proved non-inferior to pioglitazone 45 mg in reducing HbA 1C from baseline at 24 weeks. In addition, FPG levels were lower with tesaglitazar 1 mg than with pioglitazone 45 mg, which may reflect a differential effect on endogenous glucose production and hepatic insulin resistance. There was also a greater improvement in insulin sensitivity (as measured by HOMA) with tesaglitazar treatment, which could be explained by the greater reductions in FFA observed with tesaglitazar. This may be related to more potent activation of PPARα with tesaglitazar than with pioglitazone, as fibrates have been shown to lower FFA levels. 20 Thus, tesaglitazar and pioglitazone provided similar improvements in HbA 1C , but differed in their effects on other markers of glucose metabolism.
Tesaglitazar 1 mg had greater effects than pioglitazone on components of diabetic dyslipidaemia and it also lowered LDL-C more than pioglitazone. Caution is advised when interpreting this finding, as the effect of pioglitazone on LDL-C levels has not been uniform across studies, with some reports suggesting decreases, 3, 5 others indicating minor increases, 4, 6 and yet other studies and a meta-analysis reporting a neutral effect. 21, 22 Although the reductions in LDL-C levels with tesaglitazar were modest, tesaglitazar 1 mg reduced particle concentration and increased LDL particle size, effects which are associated with reduced atherosclerotic cardiovascular risk. [23] [24] [25] LDL particle number was reduced to a greater extent with tesaglitazar 1 mg than with pioglitazone, which is also known to reduce LDL particle number, 6, 21 and is consistent with observations in patients with insulin resistance. 15, 26 The greater impact of tesaglitazar on LDL particle concentration may also be partly attributable to its more potent PPARα agonism, since fibrate treatment may improve this parameter. 13 Fibrinogen was decreased more by tesaglitazar than by GALLANT 6 STUDY Key: ALT = alanine aminotransferase; ANC = absolute neutrophil count; AST = aspartate aminotransferase; GGT = gamma glutamyltransferase To convert creatinine to mg/dL multiply by 0.0113 pioglitazone; indeed, other studies have shown that pioglitazone does not affect fibrinogen concentrations, 27, 28 while fenofibrate reduces fibrinogen levels. 29 Also consistent with other observations 30, 31 was that pioglitazone reduced CRP levels; however, both tesaglitazar and pioglitazone had similar anti-inflammatory effects at their highest doses and there were no differences between them for ICAM-1 and TNF-α concentrations. CHF is a recognised, but uncommon, event with agents that have PPARγ agonist properties. 32 The low incidence of new-onset CHF in the current study makes it difficult to conclude definitively whether there is an elevated risk with tesaglitazar compared with pioglitazone. In this study, a reduction in haemoglobin also occurred, another change commonly produced by drugs with PPARγ agonist properties. 33, 34 The mechanisms underlying these changes are uncertain. Similarly, the causes of the reduction in neutrophil counts with pioglitazone and tesaglitazar are not known.
Decreases in the levels of liver enzymes have been observed in previous studies with tesaglitazar and pioglitazone. 15, 35 The reductions in ALT and AST may reflect a lowering of hepatic fat content, which is elevated in individuals with type 2 diabetes mellitus. 35 It has been proposed that an important mechanism of action of PPARγ agonists is a reduction in the fat content of the liver and the lessening of hepatic insulin resistance. 36 Because alkaline phosphatase is not produced exclusively by the liver, and because isoenzymes were not measured, it is not possible to attribute the decrease in this enzyme solely to a hepatic effect.
As previously reported, 15, 26 tesaglitazar treatment was associated with a dose-dependent increase in serum creatinine that was not accompanied by evidence of nephrotoxicity. The elevations in creatinine in this study were greater than those observed in other tesaglitazar studies, but were generally reversible following discontinuation of tesaglitazar. 15 The degree of PPARα agonism may be a contributory factor as pioglitazone (predominantly a PPARγ agonist) has not been consistently associated with elevated creatinine levels, while some fibrates (PPARα agonists) are known to increase creatinine levels in patients with type 2 diabetes mellitus and in transplant recipients. [37] [38] [39] In summary, in patients with type 2 diabetes mellitus, tesaglitazar 1 mg provided a similar reduction in HbA 1C to pioglitazone 45 mg treatment, while causing greater improvements in TG, HDL-C, non-HDL-C, LDL-C, and LDL particle size and number. However, treatment with tesaglitazar was associated with a dose-dependent increase in serum creatinine levels. In this study, both tesaglitazar and pioglitazone were associated with reports of new-onset CHF, which is a concern for existing drugs with PPARγ activity. Although the clinical development of tesaglitazar was stopped, the improvements in glycaemic control and in the lipid abnormalities of type 2 diabetes mellitus with tesaglitazar and other dual PPARα/γ agonists 8 suggest that the concept of dual PPARα/γ agonism remains worthy of further investigation. 
